Atlas Trials

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

Clinical trial NCT02335944 · TERMINATED

Trial details

NCT number
NCT02335944
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2015-01-13
Primary completion
2020-11-10
Enrollment
177

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.